Risks Associated with Use of Rupture of Membranes Tests – Letter to Health Care Providers

The FDA is reminding health care providers that tests to detect rupture of the amniotic membranes should not be used without other clinical assessments to make critical patient management decisions.

Original source: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm616220.htm

Related Posts

Leave a Reply

Your email address will not be published.